Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip

We carried out a 3 years, randomized, double-blind, placebo-controlled, multicenter clinical trial in patients with hip osteoarthritis in order to: * evaluate the ability of diacerein, an interleukin-1β inhibitor, to slow the progressive decrease in joint space width observed in patients with hip osteoarthritis * to investigate the potential structure-modifying effect of diacerein in patients with hip osteoarthritis This study compare also after ten years the percentage of patients in each treatment group who require a hip replacement surgery